Sponsor · clinical trials

Mario Negri Institute for Pharmacological Research clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our Italy, Germany, Spain, Denmark, Switzerland, Sweden and Australia registers with Mario Negri Institute for Pharmacological Research as lead sponsor. Synced 14 Nov 2026

46Current trials

23Recruiting now

12Drugs in these trials

7Trial registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany

Compiled from ClinicalTrials.gov and CTIS registry records · Synced 14 Nov 2026 · Editorial standards

At a glance

Mario Negri Institute for Pharmacological Research is the lead sponsor of 46 current clinical trials in our Italy, Germany, Spain, Denmark, Switzerland, Sweden and Australia registers. 23 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Abemaciclib, Basiliximab and Belatacept. The most-studied condition is Evaluation.

ClinicalTrials.gov trials by status

Recruiting2350%
Not yet open920%
Active, closed1430%

Trials by phase

Observational2861%
Not applicable1124%
Phase 249%
Phase 412%
Phase 2/312%
Phase 312%

Clinical trials sponsored by Mario Negri Institute for Pharmacological Research

46 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen NCT06680050 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer NSCLC Drugs: Ceralasertib, Durvalumab	Phase 2	Recruiting	2025-08	Italy, Switzerland
Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases NCT05996731 · ClinicalTrials.gov ↗ · Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, Autosomal Dominant Polycystic Kidney	Not applicable	Recruiting	2024-02	Italy
Mild TBI in the Emergency Department NCT07021118 · ClinicalTrials.gov ↗ · Emergency Departments	Observational	Recruiting	2026-01	Italy, Switzerland
Autoreactive B Cells in Membranous Nephropathy NCT04095156 · ClinicalTrials.gov ↗ · Membranous Nephropathy	Observational	Recruiting	2019-09	Italy
Trauma Molecular Processes NCT07683169 · ClinicalTrials.gov ↗ · Traumatic Brain Injury	Observational	Recruiting	2024-10	Italy
Acoustic Analysis of VA Sounds NCT05612022 · ClinicalTrials.gov ↗ · End Stage Renal Disease, Hemodialysis Access Failure	Observational	Recruiting	2023-05	Italy
RESOLving INflammation Through Diet for Health (RESOLVIN) NCT07331103 · ClinicalTrials.gov ↗ · Cardiovascular (CV) Risk, Inflammation, Omega 3	Not applicable	Recruiting	2025-11	Italy
Reproducibility of Multiparametric Renal Magnetic Resonance Imaging on 1.5T MRI Scanners NCT06884410 · ClinicalTrials.gov ↗ · Multiparametric MRI	Not applicable	Recruiting	2025-04	Germany, Spain, Italy, Denmark
Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS NCT06126315 · ClinicalTrials.gov ↗ · Amyotrophic Lateral Sclerosis	Phase 2/3	Recruiting	2025-03	Italy, Australia
Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy NCT05805202 · ClinicalTrials.gov ↗ · Atypical Hemolytic Uremic Syndrome	Not applicable	Recruiting	2023-05	Italy
Propensity to Hospitalize Patients From the ED in European Centers. NCT06354764 · ClinicalTrials.gov ↗ · Emergency Medicine	Observational	Recruiting	2025-09	Italy
Development of a Multipurpose Dashboard to Monitor the Situation of Emergency Departments NCT06372379 · ClinicalTrials.gov ↗ · Emergency Medicine	Observational	Recruiting	2025-09	Italy
Patiromer and Diet/hrQoL in Chronic Dialysis NCT06858280 · ClinicalTrials.gov ↗ · Hyperkalaemia, Chronic Kidney Disease Stage 3 and 4, Dietary Intervention Drug: Patiromer	Phase 3	Recruiting	2025-07	Italy
Development of a Natural Language Processing Tool to Enable Clinical Research in Emergency Medicine NCT06240572 · ClinicalTrials.gov ↗ · Emergency Medicine	Observational	Recruiting	2024-10	Italy
An Outcome Analysis of Primary Membranous Nephropathy NCT06242327 · ClinicalTrials.gov ↗ · Membranous Nephropathy	Observational	Recruiting	2024-11	Italy
Severe Acquired Brain Injuries: Prognostic Factors and Quality of Care NCT04905264 · ClinicalTrials.gov ↗ · Brain Injuries, Acute	Observational	Recruiting	2022-01	Italy
Kidney Perfusion With or Without Absorption NCT06374121 · ClinicalTrials.gov ↗ · Kidney Replacement	Not applicable	Recruiting	2024-10	Italy
Health-care Quality in Semi-intensive Care Units NCT04676347 · ClinicalTrials.gov ↗ · Semi-intensive Care Unit, Evaluation, Quality	Observational	Recruiting	2021-07	Italy
New Advanced Vascular Imaging Ultrasound Protocols NCT06841887 · ClinicalTrials.gov ↗ · Renal Diseases, Cerebral Disorder	Observational	Recruiting	2025-05	Italy
Blood Flow Conditions and Sounds in AVFs NCT06411353 · ClinicalTrials.gov ↗ · End Stage Renal Disease	Not applicable	Recruiting	2025-03	Italy
Autoantibodies Against-nephrin in Idiopathic Nephrotic Syndrome NCT06334692 · ClinicalTrials.gov ↗ · Nephrotic Syndrome	Observational	Recruiting	2024-03	Italy
CardioPulmonary Resuscitation With Argon (CPAr) Trial NCT05482945 · ClinicalTrials.gov ↗ · Cardiac Arrest, Out-Of-Hospital, Cardiac Arrest With Successful Resuscitation	Phase 2	Recruiting	2022-05	Italy
Evaluation of the Quality of Care in the Emergency Department by Studying the Appropriateness of Hospitalizations NCT06846879 · ClinicalTrials.gov ↗ · Quality of Care, Evaluation, Emergency Department	Observational	Recruiting	2026-01	Italy
AVF-MONITOR POC Proof-of-concept Study NCT07318025 · ClinicalTrials.gov ↗ · Hemodyalysis	Not applicable	Not yet open	2026-03	Italy
Obinutuzumab in Adult Rituximab-Dependent Nephrotic Syndrome NCT07233330 · ClinicalTrials.gov ↗ · Nephrotic Syndrome，Idiopathic Drug: Obinutuzumab	Phase 2	Not yet open	2026-02	Italy
Pilot STUDY to Monitor Ex-vivo the Biological Effects of the C3 Inhibitor, PEGCETACOPLAN, on Activation of Complement in Fluid Phase and on Podocytes in Patients With C3G and Primary IC-MPGN NCT07904338 · ClinicalTrials.gov ↗ · Glomerulopathy, C3G, Membranoproliferative Glomerulonephritis (MPGN)	Observational	Not yet open	2027-03	Italy
Mechanisms Underlying SGLT2i Kidney Effect in DKD Progression NCT07270198 · ClinicalTrials.gov ↗ · Diabetic Kidney Disease (DKD)	Not applicable	Not yet open	2026-02	Italy
Thyroid Hormones in CKD NCT07663773 · ClinicalTrials.gov ↗ · Chronic Kidney Disease (Stages 4 and 5)	Observational	Not yet open	2026-09	Italy
Emergency and Urgent Care Indicators in Piedmont NCT07606209 · ClinicalTrials.gov ↗ · Emergency Departments	Observational	Not yet open	2027-07	Italy
Omics of Rituximab-resistance NCT07416942 · ClinicalTrials.gov ↗ · Membranous Nephropathy	Observational	Not yet open	2026-04	Italy
Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib NCT07428018 · ClinicalTrials.gov ↗ · Breast Cancer, HER2 + Breast Cancer, HR Positive Drug: Abemaciclib	Phase 2	Not yet open	2026-04	Italy
Mitigating Mitochondrial RNA Release During Aging to Control Inflammation and Senescence NCT07596615 · ClinicalTrials.gov ↗ · Aging, Inflammation, Healthy Ageing	Not applicable	Not yet open	2026-09	Italy
Artificial Intelligence-based Techniques to Characterize KIdney Microstructure on Histological ImagEs NCT06690190 · ClinicalTrials.gov ↗ · End-Stage Renal Disease	Observational	Active, closed	2024-11	Italy
Simulated and Synthetic Health Data: Improving Clinical Research on Rare Diseases. A Real-World Data Simulation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Trials. A Retrospective, Observational Study NCT07016282 · ClinicalTrials.gov ↗ · Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Observational	Active, closed	2025-06	Italy, Sweden
Multiparametric MRI in Healthy Volunteers and CKD Patients NCT05229263 · ClinicalTrials.gov ↗ · Chronic Kidney Diseases, Healthy	Not applicable	Active, closed	2022-11	Germany, Spain, Italy, Denmark
New Analytic Tools for aHUS and C3G Diagnosis NCT05985122 · ClinicalTrials.gov ↗ · Hemolytic-Uremic Syndrome, Membranoproliferative Glomerulonephritis, Healthy	Not applicable	Active, closed	2023-07	Italy
Medical Images Collection Research NCT06354829 · ClinicalTrials.gov ↗ · Kidney Diseases, Brain Diseases	Observational	Active, closed	2025-01	Italy
First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients NCT06121401 · Carcinoma, Ovarian Epithelial Drugs: Bevacizumab, Olaparib	Phase 4	Active, closed	2023-09	Italy
Evaluation of the Quality of Care in the Emergency Department by Studying the Appropriateness of Admissions of Patients Accessing the Emergency Department (ASST Papa Giovanni XXIII) NCT06345378 · ClinicalTrials.gov ↗ · Quality of Care, Evaluation, Emergency Departments	Observational	Active, closed	2021-11	Italy
Evaluation of the Quality of Care in the Emergency Department by Studying the Appropriateness of Admissions of Patients Accessing the Emergency Department (Fondazione IRCCS Ca' Granda Ospedale Maggione Policlinico) NCT06345352 · ClinicalTrials.gov ↗ · Quality of Care, Evaluation, Emergency Department	Observational	Active, closed	2020-09	Italy
NASCITA Italian Birth Cohort Study NCT03894566 · ClinicalTrials.gov ↗ · Social Determinants of Health, Health Knowledge, Attitudes, Practice, Development, Child	Observational	Active, closed	2019-04	Italy
Outcome of ADPKD With Octreotide LAR NCT06193616 · ClinicalTrials.gov ↗ · Autosomal Dominant Polycystic Kidney Drug: Octreotide	Observational	Active, closed	2024-02	Italy
Comparing the Performance of Serum Creatinine and Cystatin C-based GFR Estimations in Predicting Directly Measured GFR in Patients With or Without Nephrotic Syndrome NCT06797609 · ClinicalTrials.gov ↗ · Nephrotic Syndrome	Observational	Active, closed	2025-04	Italy
Artificial Intelligence-based Image Processing Methods to Advance the Characterization of Polycystic Kidney Disease NCT06688981 · ClinicalTrials.gov ↗ · Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Observational	Active, closed	2024-10	Italy
1 vs 7 RATG Infusions in Renal Transplantation NCT06374095 · ClinicalTrials.gov ↗ · Kidney Replacement Drugs: Basiliximab, Belatacept, RATG	Observational	Active, closed	2024-07	Italy
A New Crowding Indicator in the Emergency Department NCT07111624 · ClinicalTrials.gov ↗ · Emergency Department, Crowding	Observational	Active, closed	2025-10	Italy

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Mario Negri Institute for Pharmacological Research trials

12 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Abemaciclib1 Basiliximab1 Belatacept1 Bevacizumab1 Ceralasertib1 Durvalumab1 Obinutuzumab1 Octreotide1 Olaparib1 Patiromer1 RATG1 Thymoglobulin1

Conditions in Mario Negri Institute for Pharmacological Research trials

57 conditions

Evaluation4Healthy3Emergency Departments3Membranous Nephropathy3Quality of Care3Appropriateness3Emergency Medicine3Emergency Department3Atypical Hemolytic Uremic Syndrome2Membranoproliferative Glomerulonephritis2Autosomal Dominant Polycystic Kidney2Autosomal Dominant Polycystic Kidney Disease (ADPKD)2End Stage Renal Disease2 Inflammation2Kidney Replacement2Nephrotic Syndrome2Multiparametric MRI1Chronic Kidney Diseases1Hemodyalysis1End-Stage Renal Disease1 Traumatic Brain Injury1Hemodialysis Access Failure1Cardiovascular (CV) Risk1Omega 31

By trial register

Register	Trials	Recruiting
Clinical trials in Italy	46	23
Clinical trials in Germany	2	1
Clinical trials in Spain	2	1
Clinical trials in Denmark	2	1
Clinical trials in Switzerland	2	2
Clinical trials in Sweden	1	0
Clinical trials in Australia	1	1

A trial with sites in more than one country appears in each of those registers.

Questions about Mario Negri Institute for Pharmacological Research trials

How many clinical trials does Mario Negri Institute for Pharmacological Research sponsor?

Mario Negri Institute for Pharmacological Research is the lead sponsor of 46 current trials on ClinicalTrials.gov in our Italy, Germany, Spain, Denmark, Switzerland, Sweden and Australia registers, as of the registry sync on 14 November 2026. Completed and withdrawn studies are not counted.

Are Mario Negri Institute for Pharmacological Research trials recruiting?

Yes. 23 of its 46 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Mario Negri Institute for Pharmacological Research testing?

Its current trials name 12 drugs and biologicals as interventions. The most frequent are Abemaciclib (1), Basiliximab (1), Belatacept (1), Bevacizumab (1) and Ceralasertib (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 14 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.